1.
Methods Mol Biol
; 2058: 7-29, 2020.
Artículo
en Inglés
| MEDLINE
| ID: mdl-31486029
RESUMEN
The optimal clinical exploitation of viruses as gene therapy or oncolytic vectors will require them to be administered intravenously. Strategies must therefore be deployed to enable viruses to survive the harsh neutralizing environment of the bloodstream and achieve deposition within and throughout target tissues or tumor deposits. This chapter describes the genetic and chemical engineering approaches that are being developed to overcome these challenges.